Researcher
Sofie Wilgenhof
- Keywords:Medicine
Affiliations
- Basic (bio-) Medical Sciences (Department)
Member
From1 Dec 2017 → 30 Nov 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From25 Nov 2016 → 6 Jul 2017 - Faculty of Medicine and Pharmacy (Faculty)
Member
From21 Sep 2015 → 29 Jun 2017 - Basic (bio-) Medical Sciences (Department)
Member
From1 Jan 2015 → 30 Nov 2019 - Faculty of Medicine and Pharmacy (Faculty)
Member
From28 Nov 2014 → 23 Sep 2015 - Faculty of Medicine and Pharmacy (Faculty)
Member
From2 Mar 2010 → 18 Sep 2011 - Laboratory of Molecullar and Cellular Therapy (Research group)
Member
From1 Jan 2010 → 30 Nov 2019 - Physiology (Department)
Member
From1 Oct 2009 → 30 Sep 2013
Publications
1 - 10 of 24
- TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab(2020)
Authors: Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, Isabelle Bar, Jurgen Corthals, Sofie Wilgenhof, Bart Neyns, Kris Thielemans
- Autologous mRNA electroporated dendritic cell-based immunotherapy for melanoma patients.(2017)
Authors: Sofie Wilgenhof, Kris Thielemans
- Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma(2016)
Authors: Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Nicolas Van Baren, Sophie Lucas, Pia Kvistborg, Kris Thielemans, Bart Neyns
Pages: 1330-1338 - Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma(2016)
Authors: Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jansen, Teofila Seremet, Ambre Bott, Ines Chevolet, Sofie Wilgenhof, Geert Maertens, Bart Neyns
Pages: 157-163 - Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients(2016)
Authors: Teofila Seremet, Alexander Koch, Yanina Jansen, Max Schreuer, Sofie Wilgenhof, Veronique Del Marmol, Danielle Lienard, Kris Thielemans, Kelly A Schats, Mark Kockx, et al.
- Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors(2016)
Authors: Max Schreuer, Geert Meersseman, Sari Van Den Herrewegen, Yanina Jansen, Ines Chevolet, Ambre Bott, Sofie Wilgenhof, Teofila Seremet, Bart Jacobs, Ronald Buyl, et al.
- Vemurafenib-associated Dupuytren- and Ledderhose palmoplantar fibromatosis in metastatic melanoma patients(2016)
Authors: Valerie Vandersleyen, Martine Grosber, Sofie Wilgenhof, Joery De Kock, Bart Neyns, Jan Gutermuth
Pages: 1133-1135 - Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib(2015)
Authors: Yanina Jansen, Peter Janssens, Anne Hoorens, Max Schreuer, Teofila Seremet, Sofie Wilgenhof, Bart Neyns
Pages: 550-554 - Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib(2015)
Authors: Sofie Wilgenhof, B Neyns
Pages: 109-111 - DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift(2015)
Authors: Anna L De Goede, Arno C Andeweg, Henk-Jan van den Ham, Maarten A Bijl, Fatiha Zaaraoui-Boutahar, Wilfred F J van IJcken, Sofie Wilgenhof, Joeri L Aerts, Rob A. Gruters, Albert D M E Osterhaus, et al.
Pages: 2922-2929